Compare CAN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAN | NKTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.0M | 132.8M |
| IPO Year | 2019 | 2020 |
| Metric | CAN | NKTX |
|---|---|---|
| Price | $0.43 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $3.09 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 8.9M | 668.8K |
| Earning Date | 02-10-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $1.31 |
| 52 Week High | $2.22 | $2.81 |
| Indicator | CAN | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 39.72 |
| Support Level | $0.43 | $1.95 |
| Resistance Level | $0.55 | $2.32 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 5.32 | 2.84 |
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.